Novel lactic acid bacteria and use thereof

ABSTRACT

The present invention relates to  Lactobacillus plantarum  NK3 and  Bifidobacterium longum  NK49, which are novel lactic acid bacteria and, more particularly, to a composition comprising novel lactic acid bacteria useful for prevention and treatment of inflammatory diseases.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a division, and claims priority, of co-pending U.S.application Ser. No. 16/760,689, filed Apr. 30, 2020, which is a U.S.National Stage application, and claims priority of InternationalApplication No. PCT/KR2018/004590, filed Apr. 19, 2018, which claimspriority of South Korean Application No. 10-2017-0145420, filed Nov. 2,2017. The contents of all of the prior applications are incorporatedherein by reference in their entirety.

SEQUENCE LISTING

This application contains a Sequence Listing that has been submittedelectronically as an XML file named “52068-0002002_SL_ST26.XML.” The XMLfile, created on Dec. 12, 2022, is 11,369 bytes in size. The material inthe XML file is hereby incorporated by reference in its entirety.

TECHNICAL FIELD

The present invention relates to Lactobacillus plantarum andBifidobacterium longum, which are novel lactic acid bacteria, and moreparticularly to a composition containing the novel lactic acid bacteriauseful in preventing and treating inflammatory diseases.

BCKGROUND

Inflammation is a kind of defense reaction which occurs to biologicaltissues or organs against any external stimuli. In normal cases, theinflammatory reaction removes a material infected from the outside andregenerates a damaged tissue to restore a function thereof. However, ifthe inflammatory reaction is continuously caused by the secretion ofinflammation-inducing cytokines, various inflammatory diseases occurdepending on a site where the inflammatory reaction occurs.

On the other hand, vaginitis, which is one of female inflammatorydiseases, is an intravaginal infectious disease caused by the growth ofvarious anaerobic bacteria instead of bacteria normally present in thevagina. Recently, the incidence of vaginitis has increased due towomen's greater use of feminine products and growing stress. Vaginitisis mostly bacterial vaginosis and fungal vaginitis. Bacterial vaginosisis typically caused by Gardnerella vaginalis or Atopobium vaginae, whichis an anaerobic strain. Fungal vaginitis is mainly caused by Candidaalbicans (Sexually Transmitted Diseases, November 2006, vol 33, No. 11,663-665).

Meanwhile, in case of bacterial vaginosis, symptoms may be amelioratedby using antibiotics. In case of fungal vaginitis, symptoms may beameliorated by using an azole-based antifungal agent. However, thesetherapeutic agents may cause a phenomenon of another microbialsubstitution and thus have a problem in that it is difficult to expect afundamental therapeutic effect. Thus, there is a need to develop atherapeutic agent capable of suppressing the inflammatory reaction so asto restore normal lactic acid bacteria while removing thevaginitis-causing bacteria from the vagina. However, research has notbeen sufficiently conducted.

Against these backdrops, while studying agents for preventing andtreating inflammatory diseases, particularly vaginitis, the presentinventors have identified that novel lactic acid bacteria isolated fromkimchi and human feces may be valuably used in preventing and treatinginflammatory diseases, particularly vaginitis not only by inhibitinginflammatory reactions, but also by showing a therapeutic effect onvaginitis while inhibiting the growth of vaginitis-causing bacteria, andthus have completed the present invention.

DETAILED DESCRIPTION OF THE INVENTION Technical Problem

An objective of the present invention is to provide novel lactic acidbacteria of Lactobacillus plantarum and Bifidobacterium longum.

Another objective of the present invention is to provide a compositionfor preventing or treating inflammatory diseases, containing novellactic acid bacteria.

Still another objective of the present invention is to provide a healthfunctional food for preventing or ameliorating inflammatory diseases,containing novel lactic acid bacteria.

Technical Solution

In one aspect for achieving said objectives, the present inventionprovides Lactobacillus plantarum NK3 (depository institution: the KoreanCulture Center of Microorganisms (KCCM), date of deposit: Aug. 4, 2017,and accession number: KCCM12089P).

The Lactobacillus plantarum NK3 of the present invention has a featureof being a novel lactic acid bacterium of Lactobacillus plantarum, whichis isolated and identified from kimchi, which is a traditional fermentedfood.

A 16S rDNA sequence for identification and classification ofLactobacillus plantarum NK3 of the present invention is the same as SEQID NO: 1 attached to the present specification. Thus, Lactobacillusplantarum NK3 of the present invention may include the 16S rDNA of SEQID NO: 1.

As a result of analyzing said 16S rDNA sequence of SEQ ID NO: 1, thissequence was 99% homologous to that of generally known Lactobacillusplantarum strains, thus showing the highest molecular phylogeneticrelationship with Lactobacillus plantarum. Thus, said lactic acidbacterium was identified as Lactobacillus plantarum, then named asLactobacillus plantarum NK3, and then deposited to the KCCM on Aug. 4,2017 (accession number: KCCM12089P).

The Lactobacillus plantarum NK3 of the present invention is agram-positive bacterium and a cell form thereof is bacillus. Moreparticularly, the physiological characteristics of Lactobacillusplantarum NK3 may be analyzed according to a conventional method in theart, and the results thereof are as shown in a following table 2.Particularly, Lactobacillus plantarum NK3 may use the following as acarbon source: L-arabinose, D-ribose, D-galactose, D-glucose,D-fructose, D-mannose, mannitol, sorbitol, α-methyl-D-mannoside,N-acetyl-glucosamine, amygdaline, arbutin, esculin, salicin, cellobiose,maltose, lactose, melibiose, sucrose, trehalose, melezitose,gentiobiose, D-turanose and gluconate.

In another aspect for achieving said objectives, the present inventionprovides Bifidobacterium longum NK49 (depository institution: the KoreanCulture Center of Microorganisms (KCCM), date of deposit: Aug. 4, 2017,and accession number: KCCM12088P).

The Bifidobacterium longum NK49 of the present invention has a featureof being a novel lactic acid bacterium of Bifidobacterium longum, whichis isolated and identified from human feces.

A 16S rDNA sequence for identification and classification ofBifidobacterium longum NK49 of the present invention is the same as SEQID NO: 2 attached to the present specification. Thus, Bifidobacteriumlongum NK49 of the present invention may include the 16S rDNA of SEQ IDNO: 2.

As a result of analyzing said 16S rDNA sequence of SEQ ID NO: 2, thissequence was 99% homologous to that of generally known Bifidobacteriumlongum strains, thus showing the highest molecular phylogeneticrelationship with Bifidobacterium longum. Thus, said lactic acidbacterium was identified as Bifidobacterium longum, then named asBifidobacterium longum NK49, and then deposited to the KCCM on Aug. 4,2017 (accession number: KCCM12088P).

The Bifidobacterium longum NK49 of the present invention is agram-positive bacterium and a cell form thereof is bacillus. Moreparticularly, the physiological characteristics of Bifidobacteriumlongum NK49 may be analyzed according to a conventional method in theart, and the results thereof are as shown in a following table 3.Particularly, Bifidobacterium longum NK49 may use the following as acarbon source: L-arabinose, D-ribose, D-xylose, D-galactose, D-glucose,D-fructose, mannitol, sorbitol, α-methyl-D-glucoside, esculin, salicin,maltose, lactose, melibiose, sucrose, raffinose and D-turanose.

In still another aspect for achieving said objectives, the presentinvention provides a pharmaceutical composition for preventing ortreating inflammatory diseases, containing Lactobacillus plantarum NK3KCCM12089P, Bifidobacterium longum NK49 KCCM12088P or a mixture thereof.

The “Lactobacillus plantarum NK3” of the present invention is the sameas described above.

Particularly, the Lactobacillus plantarum NK3 contained in thepharmaceutical composition of the present invention may be a livebacterial cell thereof, a dead bacterial cell thereof, a culture productthereof, a crushed product thereof or an extract thereof, but any typeof Lactobacillus plantarum NK3 may be used without limitation, as longas it may achieve a preventive or therapeutic effect on inflammatorydiseases.

The “Bifidobacterium longum NK49” of the present invention is the sameas described above.

Particularly, the Bifidobacterium longum NK49 contained in thepharmaceutical composition of the present invention may be a livebacterial cell thereof, a dead bacterial cell thereof, a culture productthereof, a crushed product thereof or an extract thereof, but any typeof Lactobacillus plantarum NK3 may be used without limitation, as longas it may achieve a preventive or therapeutic effect on inflammatorydiseases.

In the present invention, the term “culture product” means an objectobtained by culturing a lactic acid bacterium in a generally knownliquid medium or solid medium, and is a concept encompassing a novellactic acid bacterium in the present invention.

An inflammatory disease of the present invention may be at least oneselected from the group including arthritis, gout, hepatitis, asthma,obesity, corneitis, gastritis, enteritis, nephritis, colitis, diabetes,tuberculosis, bronchitis, pleurisy, peritonitis, spondylitis,pancreatitis, inflammatory pain, urethritis, cystitis, vaginitis,arteriosclerosis, septicemia, burn, dermatitis, periodontitis andgingivitis.

In one embodiment of the present invention, it was identified that aninflammatory reaction is remarkably inhibited when macrophage isolatedfrom a mouse is treated with Lactobacillus plantarum NK3 orBifidobacterium longum NK49 along with lipopolysaccharide, which is aninflammatory reaction inducer (FIGS. 1 and 2 ). From the results, it wasidentified that the pharmaceutical composition containing saidLactobacillus plantarum NK3, Bifidobacterium longum NK49 or a mixturethereof may be valuably used in preventing and treating inflammatorydiseases.

Particularly, said inflammatory disease may be vaginitis.

In one embodiment of the present invention, it was identified thatLactobacillus plantarum NK3, Bifidobacterium longum NK49 or a mixturethereof shows an effect of inhibiting the growth of Gardnerellavaginalis and Atopobium vaginae, which are vaginitis-inducing bacteria,and has an excellent effect of inhibiting infection with saidGardnerella vaginalis (FIGS. 3 to 5 ). Also, in one embodiment of thepresent invention, as a result of administering Lactobacillus plantarumNK3, Bifidobacterium longum NK49 or a mixture thereof into an animalmodel with induced vaginitis, it was identified that inflammations withedema caused by vaginitis bacteria and the number of vaginitis bacteriaare decreased, an activity of myeloperoxidase, which is a representativeinflammatory indicator in the vagina, is decreased, an expression ofTNF-α is increased in the vaginal mucosa, and an expression of IL-10 isincreased (FIGS. 6 to 10 ). From the results, it was identified that thepharmaceutical composition containing the Lactobacillus plantarum NK3,Bifidobacterium longum NK49 or a mixture thereof may be valuably used inpreventing and treating vaginitis, which is a particular inflammatorydisease.

Particularly, said inflammatory disease may be colitis.

In one embodiment of the present invention, as a result of administeringLactobacillus plantarum NK3, Bifidobacterium longum NK49 or a mixturethereof into an animal model with induced colitis, it was identifiedthat a length of colon is recovered, an activity of myeloperoxidase isdecreased, and the expression level and activity of cytokines, which arean inflammatory indicator, are inhibited (Table 6). From the results, itwas identified that the pharmaceutical composition containing theLactobacillus plantarum NK3, Bifidobacterium longum NK49 or a mixturethereof may be valuably used in preventing and treating colitis, whichis a particular inflammatory disease.

The pharmaceutical composition according to the present invention may beprepared into a pharmaceutical dosage form by a well-known method in theart, so that an active component of the composition may be provided viaa fast, suspended or prolonged release, after being administered into amammal. When preparing a dosage form, the pharmaceutical compositionaccording to the present invention may further contain apharmaceutically acceptable carrier, to the extent that this carrierdoes not suppress an activity of a novel lactic acid bacterium.

Said pharmaceutically acceptable carrier may include conventionally usedones, for example, lactose, dextrose, sucrose, sorbitol, mannitol,xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin,calcium phosphate, calcium silicate, cellulose, methyl cellulose,microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate,mineral oil and the like, but is not limited thereto. Also, thepharmaceutical composition of the present invention may contain adiluent or an excipient such as filler, extender, binder, humectant,disintegrant, surfactant, etc., or other pharmaceutically acceptableadditives.

A dosage of the pharmaceutical composition according to the presentinvention needs to be a pharmaceutically effective amount. The“pharmaceutically effective amount” means an amount enough to prevent ortreat inflammatory diseases at a reasonable benefit/risk ratioapplicable to medical treatment. An effective dose level may bevariously selected by those skilled in the art according to factors suchas a formulation method, a patient's condition and weight, the patient'sgender, age and degree of disease, a drug form, an administration routeand period, an excretion rate, reaction sensitivity, etc. The effectiveamount may vary depending on a route of treatment, a use of excipientsand a possibility of being used with other drugs, as recognized by thoseskilled in the art. However, in case of a preparation for oraladministration to achieve a preferable effect, the composition of thepresent invention may be generally administered into an adult in anamount of 0.0001 to 100 mg/kg a day, preferably 0.001 to 100 mg/kg a daybased on 1 kg of body weight. When the preparation is administered asabove, Lactobacillus plantarum NK3, Bifidobacterium longum NK49 or amixture thereof according to the present invention may be administeredin an amount of 1×10² CFU/kg to 1×10¹¹ CFU/kg a day. This administrationmay be done once a day or several times a day by dividing thepreparation. Said dosage does not limit the scope of the presentinvention in any aspect.

The pharmaceutical composition of the present invention may beadministered to mammals such as mice, livestock, humans, etc. throughvarious routes. Particularly, the pharmaceutical composition of thepresent invention may be orally or parenterally administered (forexample, applied or injected intravenously, subcutaneously orintraperitoneally), but may be preferably orally administered. Thepharmaceutical composition may be intravaginally administered to preventand treat vaginitis. A solid preparation for oral administration mayinclude powder, granule, tablet, capsule, soft capsule, pill, etc. Aliquid preparation for oral administration may include a suspendingagent, liquid for internal use, emulsion, syrup, aerosol, etc., but mayalso include various excipients, for example, humectant, sweeteningagent, flavoring agent, preservative, etc. in addition to water andliquid paraffin, which are frequently used simple diluents. Apreparation for parenteral administration may be used by beingformulated into a dosage form of external preparation and sterilizedinjectable preparation such as sterilized aqueous solution, liquid,non-aqueous solvent, suspending agent, emulsion, eye drop, eye ointment,syrup, suppository, aerosol, etc., according to respective conventionalmethods, and preferably may be used by preparing a pharmaceuticalcomposition of cream, gel, patch, spray, ointment, plaster, lotion,liniment, eye ointment, eye drop, paste or cataplasma, but is notlimited thereto. A preparation for local administration may be ananhydrous or aqueous form depending on a clinical prescription. As thenon-aqueous solvent and the suspending agent above, propylene glycol,polyethylene glycol, vegetable oil like olive oil, injectable ester likeethyl oleate, etc. may be used. As a base of the suppository, thefollowing may be used: Witepsol, Macrogol, TWEEN 61, cacao butter,laurinum, glycerogelatin, etc.

In still another aspect for achieving said objectives, the presentinvention provides a method for preventing or treating inflammatorydiseases, including administering Lactobacillus plantarum NK3,Bifidobacterium longum NK49 or a mixture thereof into a subject.

In the present invention, the terms “Lactobacillus plantarum NK3,”“Bifidobacterium longum NK49,” “administration,” “inflammatory disease”and the like are the same as described above.

Said subject refers to an animal, and may be typically a mammal, onwhich treatment using the novel lactic acid bacteria of the presentinvention may show a beneficial effect. A preferable example of thissubject may include primates like humans. Also, these subjects mayinclude all the subjects having a symptom of inflammatory diseases, orhaving a risk of having the symptom.

In still another aspect, the present invention provides a healthfunctional food for preventing or ameliorating inflammatory diseases,containing Lactobacillus plantarum NK3 KCCM12089P, Bifidobacteriumlongum NK49 KCCM12088P or a mixture thereof.

In the present invention, the terms “Lactobacillus plantarum NK3,”“Bifidobacterium longum NK49,” “administration,” “inflammatory disease”and the like are the same as described above.

The health functional food, which puts an emphasis on a body modulatingfunction of food, is a food, which is given value added to work andexpress for a particular purpose by using a physical, biochemical orbioengineering method. A component of this health functional food isdesigned and processed to fully exert a body modulating function invivo, which is involved in defending a living body, adjusting a bodyrhythm, preventing a disease and recovering from the disease, and maycontain food supplementary additives, sweeteners or functional rawmaterials, which are acceptable as food.

In case of using Lactobacillus plantarum NK3 or Bifidobacterium longumNK49 of the present invention as a health functional food (or healthfunctional beverage additives), said novel lactic acid bacteria may beadded thereto as they are, used along with other food or foodingredients, or appropriately used according to a conventional method. Amixed amount of said Lactobacillus plantarum NK3 or Bifidobacteriumlongum NK49 may be appropriately determined depending on a purpose ofuse thereof (prevention, health, improvement or therapeutic treatment).

Said health functional food may contain various nutrients, vitamins,minerals (electrolytes), flavoring agents such as synthetic flavoringagents, natural flavoring agents and the like, coloring agents andenhancers (cheese, chocolate, etc.), pectic acid and salts thereof,organic acid, protective colloidal thickeners, pH adjusting agents,stabilizers, preservatives, glycerin, alcohol, carbonators used incarbonated beverages, etc. Also, the health functional food of thepresent invention may contain pulp for preparing fruit and vegetablebased beverages. These components may be used alone or in combination,and a ratio of the additives is generally selected from a range of 0.001to 50 parts by weight with regard to the total weight of thecomposition.

A type of said health functional food has no particular limitation.Food, to which said Lactobacillus plantarum NK3 or Bifidobacteriumlongum NK49 may be added, includes sausage, meats, bread, chocolates,snacks, candies, confectionery, ramen, pizza, other noodles, chewinggums, dairy products including ice creams, various soups, beverages,teas, health drinks, alcohol beverages, vitamin complexes and the like.In case of being formulated into beverages, a liquid component, which isadded to the beverages in addition to the novel lactic acid bacteria,may include various flavors, natural carbohydrates or the like as anadditional component just as contained in conventional beverages, but isnot limited thereto. The natural carbohydrates mentioned above may bemonosaccharide (ex. glucose, fructose, etc.), disaccharide (ex. maltose,sucrose, etc.) and polysaccharide (ex. conventional sugar such asdextrin, cyclodextrin, etc.), as well as sugar alcohol such as xylitol,sorbitol, erythritol, etc.

In still another aspect, the present invention provides a use ofLactobacillus plantarum NK3 KCCM12089P, Bifidobacterium longum NK49KCCM12088P or a mixture thereof for preparing a drug for treatinginflammatory diseases.

In still another aspect, the present invention provides a compositioncontaining Lactobacillus plantarum NK3 KCCM12089P, Bifidobacteriumlongum NK49 KCCM12088P or a mixture thereof for a use in treatinginflammatory diseases.

In still another aspect, the present invention provides a use ofLactobacillus plantarum NK3 KCCM12089P, Bifidobacterium longum NK49KCCM12088P or a mixture thereof for treating inflammatory diseases.

The numerical values described in the present specification as aboveshould be interpreted to include a range of equivalents thereof, unlessotherwise stated.

Hereinafter, the present invention will be described in detail throughpreferred Examples for better understanding of the present invention.However, the following Examples are provided only for the purpose ofillustrating the present invention, and thus the present invention isnot limited thereto.

Advantageous Effects

Lactobacillus plantarum NK3, Bifidobacterium longum NK49 or a mixturethereof, which is a novel lactic acid bacterium according to the presentinvention, has an effect of inhibiting inflammatory reactions. Thus, thenovel lactic acid bacteria according to the present invention may beused as a composition for preventing or treating inflammatory diseases,and particularly effective in treating and preventing colitis andvaginitis.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a graph showing inhibitory capacity of Lactobacillus plantarumNK3 and Bifidobacterium longum NK49, which are novel lactic acidbacteria, against an activity of NF-kB (p-p65/p65) to macrophage.

FIG. 2 is a graph showing inhibitory capacity of Lactobacillus plantarumNK3 and Bifidobacterium longum NK49, which are novel lactic acidbacteria, against an expression level of TNF-α to macrophage.

FIG. 3 is a graph showing an antibacterial effect of Lactobacillusplantarum NK3 and Bifidobacterium longum NK49, which are novel lacticacid bacteria, against Gardnerella vaginalis.

FIG. 4 is a graph showing an antibacterial effect of Lactobacillusplantarum NK3 and Bifidobacterium longum NK49, which are novel lacticacid bacteria, against Atopobium vaginae.

FIG. 5 is a graph showing an inhibitory capacity of Lactobacillusplantarum NK3 and Bifidobacterium longum NK49, which are novel lacticacid bacteria, against infection with Gardnerella vaginalis.

G: Group treated with Gardnerella vaginalis only; GL5, GL6, GL7: Grouptreated with Gardnerella vaginalis and then treated with Lactobacillusplantarum at 1×10⁶ CFU/mL, 1×10⁷ CFU/mL and 1×10⁸ CFU/mL respectively;and GB5, GB6, GB7: Group treated with Gardnerella vaginalis and thentreated with Bifidobacterium longum at 1×10⁶ CFU/mL, 1×10⁷ CFU/mL and1×10⁸ CFU/mL respectively.

FIG. 6 is a view showing an identified effect of Lactobacillus plantarumNK3, Bifidobacterium longum NK49 and a mixture thereof, which are novellactic acid bacteria, on inhibiting inflammations in the vagina and theuterus.

N: Normal group; GC: Group infected with Gardnerella vaginalis only;oGL, oGB, oGM: Group of experimental animals infected with Gardnerellavaginalis, orally dosed with respective Lactobacillus plantarum,Bifidobacterium longum or a mixture thereof; and vGL, vGB, vGM: Group ofexperimental animals infected with Gardnerella vaginalis, intravaginallydosed with respective Lactobacillus plantarum, Bifidobacterium longum ora mixture thereof. Hereinafter the same.

FIG. 7 is a graph showing an inhibitory capacity of Lactobacillusplantarum NK3, Bifidobacterium longum NK49 and a mixture thereof, whichare novel lactic acid bacteria, against infection with Gardnerellavaginalis.

FIG. 8 is a graph showing an inhibitory capacity of Lactobacillusplantarum NK3, Bifidobacterium longum NK49 and a mixture thereof, whichare novel lactic acid bacteria, against an activity of myeloperoxidase.

FIG. 9 is a graph showing an inhibitory capacity of Lactobacillusplantarum NK3, Bifidobacterium longum NK49 and a mixture thereof, whichare novel lactic acid bacteria, against an expression of TNF-α.

FIG. 10 is a graph showing an increasing capacity of Lactobacillusplantarum NK3, Bifidobacterium longum NK49 and a mixture thereof, whichare novel lactic acid bacteria, for an expression of IL-10.

FIG. 11 is a graph showing an effect of Lactobacillus plantarum NK3,Bifidobacterium longum NK49 and a mixture thereof, which are novellactic acid bacteria, on recovering Lactobacilli in the vagina.

MODE FOR INVENTION

Hereinafter, the present invention will be described in detail throughpreferred Examples for better understanding of the present invention.However, the following Examples are provided only for the purpose ofillustrating the present invention, and thus the present invention isnot limited thereto.

EXAMPLE 1 Isolation and Identification of Lactic Acid Bacteria

(1) Isolation of Lactic Acid Bacteria from Human Feces

Human feces were inserted and suspended in GAM liquid medium (GAM broth;Nissui Pharmaceutical, Japan). After that, the supernatant was taken andtransplanted into BL agar medium (Nissui Pharmaceutical, Japan), andthen anaerobically cultured at 37° C. for about 48 hours, so as toisolate colony-forming strains therefrom.

(2) Isolation of Lactic Acid Bacteria from Kimchi

Cabbage kimchi, radish kimchi or green onion kimchi was crushedrespectively, after which crushed supernatant was taken and transplantedinto MRS agar medium (Difco, USA), and then anaerobically cultured at37° C. for about 48 hours, so as to isolate colony-forming strainstherefrom.

(3) Identification of Isolated Lactic Acid Bacteria

Physiological characteristics and 16S rDNA sequences of the strainsisolated from human feces or kimchi were analyzed to identify species ofthe strains, and then names were given to the strains. Strain namesgiven to lactic acid bacteria are the same as shown in the followingtable 1. Particularly, the lactic acid bacteria isolated from kimchiwere five species of Lactobacillus plantarum (management nos. 1 to 5 ofTable 1), five species of Lactobacillus brevis (management nos. 6 to 10of Table 1), five species of Lactobacillus sakei (management nos. 11 to15 of Table 1), and five species of Lactobacillus curvatus (managementnos. 16 to 20 of Table 1). The lactic acid bacteria isolated from humanfeces were five species of Lactobacillus rhamnosus (management nos. 21to 25 of Table 1), five species of Lactobacillus plantarum (managementnos. 26 to 30 of Table 1), five species of Lactobacillus reuteri(management nos. 31 to 35 of Table 1), four species of Lactobacillusjohnsonii (management nos. 36 to 39 of Table 1), three species ofLactobacillus mucosae (management nos. 40 to 42 of Table 1), threespecies of Bifidobacterium adolescentis (management nos. 43 to 45 ofTable 1), and five species of Bifidobacterium longum (management nos. 46to 50 of Table 1).

TABLE 1 Management no. Strain name 1 Lactobacillus plantarum NK1 2Lactobacillus plantarum NK2 3 Lactobacillus plantarum NK3 4Lactobacillus plantarum NK4 5 Lactobacillus plantarum NK5 6Lactobacillus brevis NK6 7 Lactobacillus brevis NK7 8 Lactobacillusbrevis NK8 9 Lactobacillus brevis NK9 10 Lactobacillus brevis NK10 11Lactobacillus sakei NK11 12 Lactobacillus sakei NK12 13 Lactobacillussakei NK13 14 Lactobacillus sakei NK14 15 Lactobacillus sakei NK15 16Lactobacillus curvatus NK16 17 Lactobacillus curvatus NK17 18Lactobacillus curvatus NK18 19 Lactobacillus curvatus NK19 20Lactobacillus curvatus NK20 21 Lactobacillus rhamnosus NK21 22Lactobacillus rhamnosus NK22 23 Lactobacillus rhamnosus NK23 24Lactobacillus rhamnosus NK24 25 Lactobacillus rhamnosus NK25 26Lactobacillus plantarum NK26 27 Lactobacillus plantarum NK27 28Lactobacillus plantarum NK28 29 Lactobacillus plantarum NK29 30Lactobacillus plantarum NK30 31 Lactobacillus reuteri NK31 32Lactobacillus reuteri NK32 33 Lactobacillus reuteri NK33 34Lactobacillus reuteri NK34 35 Lactobacillus reuteri NK35 36Lactobacillus johnsonii NK36 37 Lactobacillus johnsonii NK37 38Lactobacillus johnsonii NK38 39 Lactobacillus johnsonii NK39 40Lactobacillus mucosae NK40 41 Lactobacillus mucosae NK41 42Lactobacillus mucosae NK42 43 Bifidobacterium adolescentis NK43 44Bifidobacterium adolescentis NK44 45 Bifidobacterium adolescentis NK4546 Bifidobacterium longum NK46 47 Bifidobacterium longum NK47 48Bifidobacterium longum NK48 49 Bifidobacterium longum NK49 50Bifidobacterium longum NK50

(4) Physiological Characteristics of Novel Lactic Acid BacteriumLactobacillus Plantarum NK3

Out of strains described in Table 1 above, it was identified thatLactobacillus plantarum NK3 (accession number KCCM12089P) is agram-positive bacillus. Also, it was shown that 16S rDNA ofLactobacillus plantarum NK3 has a sequence of SEQ ID NO: 1. As a resultof comparing the 16S rDNA sequence of Lactobacillus plantarum NK3through BLAST search, it was shown that a Lactobacillus plantarum strainhaving the same 16S rDNA sequence is not searched at all, and thesequence was 99% homologous to the 16S rDNA sequence of a generallyknown Lactobacillus plantarum strain.

Out of physiological characteristics of Lactobacillus plantarum NK3,availability of carbon source was analyzed with a sugar fermentationtest using API 50 CHL kit. The results thereof are the same as shown ina following table 2. In Table 2 below, “+” indicates that theavailability of carbon source is positive and “−” indicates that theavailability of carbon source is negative.

TABLE 2 Carbon source NK3 Carbon source NK3 CONTROL − Esculin + Glycerol− Salicin + Erythritol − Cellobiose + D-arabinose − Maltose +L-arabinose + Lactose + D-ribose + Melibiose + D-xylose − Sucrose +L-xylose − Trehalose + D-adonitol − Inulin − Methyl-BD-xylopyranoside −Melezitose + D-galactose + Raffinose − D-glucose + Starch − D-fructose +Glycogen − D-mannose + Xylitol − L-sorbose − Gentiobiose + Rhamnosus −D-furanose + Dulcitol − D-lyxose − Inositol − D-tagatose − Mannitol +D-fucose − Solbitol + L-fucose − α-methyl-D-mannoside ± D-arabitol −α-methyl-D-glucoside − L-arabitol − N-acetyl-glucosamine + Gluconate ±Amygdalin + 2-keto-gluconate − Arbutin + 5-keto-gluconate −

(5) Physiological Characteristics of Novel Lactic Acid BacteriumBifidobacterium Longum NK49

Out of strains described in Table 1 above, it was identified thatBifidobacterium longum NK49 (accession number KCCM12088P) is agram-positive bacillus. Also, it was shown that 16S rDNA ofBifidobacterium longum NK49 has a sequence of SEQ ID NO: 2. As a resultof comparing the 16S rDNA sequence of Bifidobacterium longum NK49through BLAST search, it was shown that a Bifidobacterium longum strainhaving the same 16S rDNA sequence is not searched at all, and 99%homologous to the 16S rDNA sequence of a generally known Bifidobacteriumlongum strain.

Out of physiological characteristics of Bifidobacterium longum NK49,availability of carbon source was analyzed with a sugar fermentationtest using API 50 CHL kit. The results thereof are the same as shown ina following table 3. In Table 3 below, “+” indicates that theavailability of carbon source is positive and “−” indicates that theavailability of carbon source is negative.

TABLE 3 Carbon source NK49 Carbon source NK49 CONTROL − Esculin +Glycerol − Salicin + Erythritol − Cellobiose − D-arabinose − Maltose +L-arabinose + Lactose + D-ribose + Melibiose + D-xylose ± Sucrose +L-xylose − Trehalose − D-adonitol − Inulin − Methyl-BD-xylopyranoside −Melezitose − D-galactose + Raffinose + D-glucose + Starch − D-fructose +Glycogen − D-mannose − Xylitol − L-sorbose − Gentiobiose − Rhamnosus −D-turanose ± Dulcitol − D-lyxose − Inositol − D-tagatose − Mannitol +D-fucose − Sorbitol + L-fucose − α-methyl-D-mannoside − D-arabitol −α-methyl-D-glucoside ± L-arabitol − N-acetyl-glucosamine − Gluconate −Amygdalin − 2-keto-gluconate − Arbutin − 5-keto-gluconate −

EXAMPLE 2 Comparison of Activity of Isolated Lactic Acid Bacteria

(1) Antioxidant Activity (In Vitro)

DPPH (2,2-Diphenyl-1-picrylhydrazyl) was dissolved in ethanol to reach a0.2 mM concentration, such that a DPPH solution was prepared. Asuspension of lactic acid bacteria (1×10⁶ CFU/ml) or a vitamin Csolution (1 g/ml) was inserted into 0.1 ml of said DPPH solution, andthen cultured at 37° C. for 20 minutes. A culture fluid was centrifugedat 3000 rpm for five minutes, such that supernatant was obtained. Afterthat, an absorbance of the supernatant was measured at 517 nm, and thenantioxidant activity of isolated lactic acid bacteria was calculatedaccordingly. Antioxidant activity for each lactic acid bacterium is thesame as shown in a following table 4.

(2) Measurement of Inflammatory Indicators in Macrophage

2 ml of sterilized 4% Thioglycolate was intraperitoneally administeredinto a C57BL/6 mouse (male, 6 weeks old and 20-23 g). In 96 hours later,the mouse was anesthetized, and then 8 ml of RPMI 1640 medium wasintraperitoneally administered to the mouse. In 5 to 10 minutes later,the RPMI medium (macrophage) was intraperitoneally extracted from themouse, then centrifuged at 1000g for 10 minutes, and then washed twiceagain with RPMI 1640 medium. Said macrophage was plated in a 24-wellplate at 0.5×10⁶ per well, and then treated with the isolated lacticacid bacteria (final treatment concentration: 1×10⁴ cfu/ml, hereinafterthe same) and lipopolysaccharide (LPS), which is an inflammatoryreaction inducer, for 2 or 24 hours, such that supernatant and cellswere obtained therefrom. The obtained cells were inserted into an RIPAbuffer (Gibco) and homogenized. An expression level of cytokines such asTNF-α, IL-10, etc. was measured from a culture supernatant treated for24 hours and expression levels of p65 (NF-κB), p-p65 (phosphor-NF-κB)and (β-actin were measured from the cells obtained with treatment fortwo hours through an immunoblotting method. Expression levels ofinflammation indicators for each lactic acid bacterium are the same asshown in a following table 4.

(Criteria when measuring activity in Table 4: +++, >90%, very strong;++, >60-90%, strong; +, >20-60%, weak; and −, <20%, insignificanteffect, the same as Table 5)

TABLE 4 TNF-α IL-10 NF-kB Antioxidant inhibitory expression inhibitoryManagement no. Strain name activity capacity increase capacity 1Lactobacillus plantarum NK1 + + + + 2 Lactobacillus plantarum NK2 +++ + + 3 Lactobacillus plantarum NK3 +++ +++ +++ +++ 4 Lactobacillusplantarum NK4 + + + ++ 5 Lactobacillus plantarum NK5 ++ ++ ++ ++ 6Lactobacillus brevis NK6 + + + + 7 Lactobacillus brevis NK7 + + + + 8Lactobacillus brevis NK8 + + + + 9 Lactobacillus brevis NK9 + + + + 10Lactobacillus brevis NK10 − + + + 11 Lactobacillus sakei NK11 + + + + 12Lactobacillus sakei NK12 − ++ + + 13 Lactobacillus sakei NK13 − ++ ++ +14 Lactobacillus sakei NK14 − + + + 15 Lactobacillus sakei NK15 + + + +16 Lactobacillus curvatus NK16 + + + + 17 Lactobacillus curvatusNK17 + + + + 18 Lactobacillus curvatus NK18 + + + + 19 Lactobacilluscurvatus NK19 + + + + 20 Lactobacillus curvatus NK20 + + + + 21Lactobacillus rhamnosus NK21 + + + + 22 Lactobacillus rhamnosusNK22 + + + + 23 Lactobacillus rhamnosus NK23 + + + + 24 Lactobacillusrhamnosus NK24 ++ + + + 25 Lactobacillus rhamnosus NK25 ++ ++ ++ ++ 26Lactobacillus plantarum NK26 + + + + 27 Lactobacillus plantarumNK27 + + + + 28 Lactobacillus plantarum NK28 + + + + 29 Lactobacillusplantarum NK29 + + + + 30 Lactobacillus plantarum NK30 + + + + 31Lactobacillus reuteri NK31 + + + + 32 Lactobacillus reuteri NK32 ++ ++++ ++ 33 Lactobacillus reuteri NK33 +++ ++ ++ ++ 34 Lactobacillusreuteri NK34 + + + + 35 Lactobacillus reuteri NK35 + + + + 36Lactobacillus johnsonii NK36 ++ ++ ++ + 37 Lactobacillus johnsonii NK37++ ++ ++ ++ 38 Lactobacillus johnsonii NK38 + + + + 39 Lactobacillusjohnsonii NK39 + + + + 40 Lactobacillus mucosae NK40 ++ ++ ++ ++ 41Lactobacillus mucosae NK41 ++ ++ +++ +++ 42 Lactobacillus mucosaeNK42 + + + + 43 Bifidobacterium adolescentis NK43 + + + + 44Bifidobacterium adolescentis NK44 ++ ++ ++ ++ 45 Bifidobacteriumadolescentis NK45 + + + + 46 Bifidobacterium longum NK46 +++ ++ +++ +++47 Bifidobacterium longum NK47 ++ ++ ++ ++ 48 Bifidobacterium longumNK48 + + + + 49 Bifidobacterium longum NK49 +++ +++ +++ +++ 50Bifidobacterium longum NK50 + + + +

(3) Effect on ZO-1 Protein Expression in Caco2 Cells

Caco2 cells, which are colon cancer cells, were purchased from theKorean Cell Line Bank, then cultured in RPMI 1640 medium for 48 hours,and then were seeded in a 12-well plate at 2×10⁶ cells per well. Eachwell was treated with 1 μg of LPS only, or treated with 1 μg of LPS and1×10⁴ CFU of lactic acid bacteria together, and then cultured for 24hours. After that, the cultured cells were collected from each well, andan expression level of ZO-1, which is a tight junction protein, wasmeasured by an immunoblotting method. Expression levels of ZO-1 for eachlactic acid bacterium are the same as shown in a following table 5.

TABLE 5 ZO-1 Expression Management no. Strain name increase 1Lactobacillus plantarum NK1 + 2 Lactobacillus plantarum NK2 + 3Lactobacillus plantarum NK3 ++ 4 Lactobacillus plantarum NK4 + 5Lactobacillus plantarum NK5 ++ 6 Lactobacillus brevis NK6 + 7Lactobacillus brevis NK7 + 8 Lactobacillus brevis NK8 + 9 Lactobacillusbrevis NK9 + 10 Lactobacillus brevis NK10 − 11 Lactobacillus sakeiNK11 + 12 Lactobacillus sakei NK12 − 13 Lactobacillus sakei NK13 + 14Lactobacillus sakei NK14 + 15 Lactobacillus sakei NK15 + 16Lactobacillus curvatus NK16 + 17 Lactobacillus curvatus NK17 + 18Lactobacillus curvatus NK18 + 19 Lactobacillus curvatus NK19 + 20Lactobacillus curvatus NK20 + 21 Lactobacillus rhamnosus NK21 + 22Lactobacillus rhamnosus NK22 + 23 Lactobacillus rhamnosus NK23 + 24Lactobacillus rhamnosus NK24 ++ 25 Lactobacillus rhamnosus NK25 + 26Lactobacillus plantarum NK26 + 27 Lactobacillus plantarum NK27 + 28Lactobacillus plantarum NK28 + 29 Lactobacillus plantarum NK29 + 30Lactobacillus plantarum NK30 + 31 Lactobacillus reuteri NK31 + 32Lactobacillus reuteri NK32 ++ 33 Lactobacillus reuteri NK33 ++ 34Lactobacillus reuteri NK34 + 35 Lactobacillus reuteri NK35 + 36Lactobacillus johnsonii NK36 + 37 Lactobacillus johnsonii NK37 ++ 38Lactobacillus johnsonii NK38 + 39 Lactobacillus johnsonii NK39 + 40Lactobacillus mucosae NK40 ++ 41 Lactobacillus mucosae NK41 ++ 42Lactobacillus mucosae NK42 + 43 Bifidobacterium adolescentis NK43 + 44Bifidobacterium adolescentis NK44 ++ 45 Bifidobacterium adolescentisNK45 + 46 Bifidobacterium longum NK46 ++ 47 Bifidobacterium longumNK47 + 48 Bifidobacterium longum NK48 + 49 Bifidobacterium longum NK49 +50 Bifidobacterium longum NK50 +

(5) Experimental Results

As a result of evaluating an activity of isolated lactic acid bacteria,it was identified that Lactobacillus plantarum NK3 and Bifidobacteriumlongum NK49, which are novel lactic bacteria out of the isolated lacticacid bacteria, increase an expression level of ZO-1, which is a tightjunction protein, thereby showing an excellent antioxidant activity andan excellent effect of inhibiting inflammatory reactions (Tables 4 and5).

EXAMPLE 3 Measurement of Inhibitory Capacity Against InflammatoryReactions of Macrophage

In Example 2 above, it was identified that there is an effect ofinhibiting inflammatory reactions depending on a concentration ofadministration of Lactobacillus plantarum NK3 and Bifidobacterium longumNK49, which are novel lactic acid bacteria having excellent antioxidantactivity and an excellent effect of inhibiting inflammatory reactions.

Particularly, 2 ml of sterilized 4% Thioglycolate was intraperitoneallyadministered into a C57BL/6 mouse (male, 20-23 g). In 96 hours later,the mouse was anesthetized, and then 8 ml of RPMI 1640 medium wasintraperitoneally administered into the mouse. In 5 to 10 minutes later,the RPMI medium (macrophage) was intraperitoneally extracted from themouse, then centrifuged at 1000 g for 10 minutes, and then washed twiceagain with RPMI 1640 medium. After being cultured in a 24-well plate forfive hours, attached cells were used as macrophage. The macrophage wasplated at 0.5×10⁶ per well, and treated with 10³, 10⁴ and 10⁵ CFU/mL ofLactobacillus plantarum NK3 and Bifidobacterium longum NK49, which arenovel lactic acid bacteria, as well as lipopolysaccharide (LPS), whichis an inflammatory reaction inducer, for 90 minutes or 24 hours, suchthat supernatant and cells were obtained therefrom. The obtained cellswere inserted into an RIPA buffer (Gibco) and homogenized. Expressionlevels of p65 (NF-κB), p-p65 (phosphor-NF-kB) and (β-actin were measuredfrom the cells obtained with treatment for 90 minutes through animmunoblotting method. An expression level of TNF-α cytokines wasmeasured by ELISA kit (Ebioscience, San Diego, Calif., USA) from theculture supernatant obtained after treatment for 24 hours.

In result, it was identified that an activity of NF-kB is inhibited andan expression level of TNF-α is inhibited in all the groups treated withLactobacillus plantarum NK3 or Bifidobacterium longum NK49 (FIGS. 1 and2 ).

EXAMPLE 4 Antibacterial Activity Against vaginitis-Causing Bacteria

(1) Antibacterial Test of Lactic Acid Bacteria

Lactobacillus plantarum NK3 and Bifidobacterium longum NK49 (1×10⁶,1×10⁷, 1×10⁸ CFU/mL), which were the isolated novel lactic acidbacteria, were transplanted into GAM medium along with Gardnerellavaginalis or Atopobium vaginae (1×10⁶ CFU/mL). Culture was performed for24 hours at 37° C. under an anaerobic condition in BHIS medium, in whichyeast extract (1%), maltose (0.1%), glucose (0.1%) and horse serum (10%)were added into BHI broth, such that antibacterial activity wasmeasured.

In result, it was identified that both Lactobacillus plantarum NK3 andBifidobacterium longum NK49 show an effect of inhibiting growth ofGardnerella vaginalis and Atopobium vaginae by 95% or more (FIGS. 3 and4 ).

(2) Infection Inhibitory Capacity of Lactic Acid Bacteria

While HeLa cells, which are a human cervical cancer cell line, werecultured in RPMI 1640 medium (containing 10% heat-inactivated fetal calfserum) at 37° C., 5% CO₂ and 95% air conditions, Lactobacillus plantarumNK3 and Bifidobacterium longum NK49 (1×10⁴, 1×10⁶ CFU/mL), which werethe isolated lactic acid bacteria, were transplanted thereinto alone orin combination with said lactic acid bacteria (1×10⁵, 1×10⁶, 1×10⁷CFU/mL) as well as Gardnerella vaginalis (1×10⁵ CFU/mL), such that thenumber of bacteria attached to the HeLa cells was measured through qPCRin 24 hours later.

In result, it was identified that the number of Gardnerella vaginalisattached is remarkably decreased in the HeLa cells, into whichLactobacillus plantarum NK3 or Bifidobacterium longum NK49 wastransplanted together (FIG. 5 ).

From the above experimental results, it can be understood that the novellactic acid bacteria show not only an effect of inhibiting the growth ofvaginitis-inducing bacteria, but also an effect of inhibiting infectionwith bacteria.

EXAMPLE 5 Effect of Lactic Acid Bacteria on Treating Vaginitis in AnimalModel

(1) Preparation of Animal Model with Vaginitis and Administration ofLactic Acid Bacteria

An experiment was performed by using six C57BL/6 mice (female, 19-22 gand 6 weeks old) per group. 0.125 mg of β-estradiol 17-benzoate (SigmaInc., MO, USA) was dissolved in olive oil and subcutaneously injectedinto each of said mice. Three days later, Gardnerella vaginalis (1×10⁸CFU/mouse) was transplanted into the vagina of the mouse. Lactobacillusplantarum NK3, Bifidobacterium longum NK49 or a 1:1 mixture thereof,which was the isolated novel lactic acid bacteria, was administeredorally into the mouse or directly into the vagina thereof at 1×10⁹CFU/mouse once every day for 14 days from the 8th day aftertransplantation. The last administration was performed on the 7th dayafter the administration of lactic acid bacteria (14th day aftertransplantation), and an animal model was sacrificed in 24 hours laterto perform an experiment.

(2) Identification of Occurrence of Intravaginal Inflammations

As a result of transplanting Gardnerella vaginalis into the vagina ofthe mouse as above, an inflammation with edema occurred to the vaginaand the uterus. However, as a result of orally or intravaginallyadministering Lactobacillus plantarum NK3, Bifidobacterium longum NK49or a mixture thereof, which is a novel lactic acid bacterium, it wasidentified that inflammations are significantly decreased in appearancein the vagina and the uterus (FIG. 6 ).

(3) Quantification of Lactic Acid Bacteria and Gardnerella VaginalisStrains

After administering the novel lactic acid bacteria as above, the insideof the vagina was washed with 0.5 ml of sterilized saline solution in 24and 48 hours later. A resultant vaginal wash liquid was isolated withQaigen DNA purification kit, after which lactic acid bacteria andGardnerella vaginalis strains were quantified through PCR.

In result, it was identified that the number of infectious Gardnerellavaginalis bacteria is decreased by 99% or more in the group orally orintravaginally dosed with Lactobacillus plantarum NK3, Bifidobacteriumlongum NK49 or a mixture thereof (FIG. 7 ).

(4) Measurement of Myeloperoxidase Activity

A vaginal wash liquid obtained as above was added into 1 mL of 50 mMphosphate buffer (pH 6.0) and subjected to supersonic treatment. Aprocess of thawing and freezing was performed three times, followed bycentrifugation. 398 μL of o-dianisidine (0.129 mg/mL) was added into 100μL of supernatant. A final concentration of H₂O₂ was set to 0.0005%,after which activity of myeloperoxidase (MPO) was measured at 25° C. andat 492 nm during time course.

In result, in case of the group infected with Gardnerella vaginalis, theactivity of myeloperoxidase, which is a representative inflammationindicator of the vagina, was significantly increased. In case of thegroup orally or intravaginally dosed with Lactobacillus plantarum NK3,Bifidobacterium longum NK49 or a mixture thereof, however, it wasidentified that the activity of myeloperoxidase is remarkably decreased(FIG. 8 ).

(5) Analysis of Transcription Factors and Cytokines in Vaginal Mucosa

Lysis buffer (20 mM HEPES, 1.5 mM MgCl2, 0.4 mM NaCl, 1 mM EDTA, 1 mMdithiotheitol, 0.5 mM phenyl methyl sulfonyl fluoride, 20 μg/mL trypsininhibitor, 1% NONIDET P-40, 20% glycerol) was injected into the colon orvaginal mucosa tissues of the animal model sacrificed above and washomogenized. A specimen was prepared to contain 50 μg/μL of proteins byquantifying the proteins with Bradford assay. 10 μg/μL ofelectrophoretic sample buffer (Laemmli sample buffer 950 μL+βMe 50 μL)was added into the specimen and denatured at 100° C. for three minutesto carry out electrophoresis (150 V, 30 mA). The electrophoresed gel wastransferred to a membrane at 30 V for two hours. Said membrane wasinserted into 5% skim milk/PBS-T (0.05% TWEEN 20/PBS) in an amount of 15ml and shaken for one hour. 10 mL of 1% skim milk/PBS-T was insertedinto 10 μg/μL of primary antibodies, then subjected to reaction for 12hours, and then washed with PBS-T solution for five minutes three times.And, 20 mL of 1% skim milk/PBS-T was inserted into 10 μg/μL of secondaryantibodies with regard to each of cytokines and transcription factors,and then subjected to reaction by shaking for one hour. Washing wasperformed with PBS-T solution for five minutes three times and ECLsolution was subjected to luminescence at last.

In result, in case of the group infected with Gardnerella vaginalis, anexpression of TNF-α was increased and an expression of IL-10 wasdecreased in vaginal tissues. However, in case of the group orally orintravaginally dosed with Lactobacillus plantarum NK3, Bifidobacteriumlongum NK49 or a mixture thereof, it was identified that an expressionof TNF-α is inhibited and an expression of IL-10 is increased (FIGS. 9and 10 ).

(6) Increase in Intravaginal Lactic Acid Bacteria

The inside of the vagina of the mouse was washed twice with 0.5 ml ofsterilized saline solution. A resultant vaginal wash liquid wascollected and centrifuged (10,000 g, 10 minutes), and DNA was extractedfrom precipitates by using a bacterial genomic DNA extraction kit(QIAGEN DNeasy Feces kit; Qiagen, Hilden, Germany). 10 ng of theextracted DNA was inserted into Qiagen thermal cycler and the followingprimers and SYBER premix were inserted thereinto, after which PCR wasperformed by carrying out DNA polymerase activation (95° C., 30seconds), denaturation (95° C., 5 seconds) and amplification (63° C., 30seconds) 38 times.

Lactobacilli forward (5′-3′) (SEQ ID NO: 3) CTC AAA ACT AAA CAA AGT TTC;Lactobacilli reverse (5′-3′) (SEQ ID NO: 4) CTT GTA CAC ACC GCC CGT;Control 16S rDNA forward (5′-3′) (SEQ ID NO: 5)AGA GTT TGA TCC TGG CTC AG; and Control 16S rDNA reverse (5′-3′)(SEQ ID NO: 6) AAG GAG GTG WTC CAR CC.

In result, in case of being infected with Gardnerella vaginalis, it wasidentified that Lactobacilli are remarkably decreased. On the otherhand, in case of being orally or intravaginally dosed with Lactobacillusplantarum NK3, Bifidobacterium longum NK49 or a mixture thereof, it wasidentified that said Lactobacilli are increased (FIG. 11 ). It meansthat Lactobacilli, which are decreased due to vaginitis induced byGardnerella vaginalis, are recovered by the administration of saidlactic acid bacteria, so as to restore acidic conditions inside thevagina.

From the above experimental results, it was identified that the novellactic acid bacteria have an effect on preventing and treatingvaginitis.

EXAMPLE 5 Therapeutic Effect of Lactic Acid Bacteria on Colitis inAnimal Model (1) Preparation of Animal Model with Colitis andAdministration of Lactic Acid Bacteria

An experiment was performed by using six C57BL/6 mice (male, 21-23 g and6 weeks old) per group after being acclimated in a laboratory for oneweek. One group was a normal group and the mice in the rest of thegroups were induced to develop colitis with2,4,6-trinitrobenzenesulfonic acid (TNBS). Particularly, theexperimental animals were anesthetized with ether, after which 0.1 ml ofTNBS solution mixed in 50% ethanol was rectally administered into eachcolon of animals by using a 1 ml syringe with a round top, and then theanimals were vertically lifted and maintained for 30 seconds to induceinflammations therefrom. On the other hand, the normal group was orallydosed with 0.1 ml of saline solution. Lactobacillus plantarum NK3,Bifidobacterium longum NK49 or a 1:1 mixture thereof, which is a novellactic acid bacterium, was suspended in saline solution and orallyadministered in an amount of 1×10⁹ CFU once daily for three daysstarting from the following day after administration. On the next dayafter finishing the administration of lactic acid bacteria, theexperimental animals were sacrificed, after which a colon ranging fromappendix to a region right before anus was removed from a largeintestine and a length thereof was measured. After that, the followingvarious indicators were identified from the above. On the other hand,the experimental animals of the normal group were orally dosed with 1%dextrose solution, which was suspension of lactic acid bacteria, insteadof the novel lactic acid bacteria. Also, the experimental animals of thepositive control group were orally dosed with 50 mg/kg of Sulfasalazine,which was a therapeutic drug for colitis, instead of the novel lacticacid bacteria.

(2) Measurement of Myeloperoxidase Activity

200 μl of 10 mM potassium phosphate buffer (pH 7.0) containing 0.5%hexadecyl trimethyl ammonium bromide was put into 100 mg of colontissues, and subjected to homogenization. A resulting product wascentrifuged at 4° C. and at 10,000 g for 10 minutes, so as to obtain asupernatant therefrom. 50 μl of the supernatant was put into 0.95 μl ofa reaction solution (containing 1.6 mM tetramethyl benzidine and 0.1 mMH₂O₂), and then subjected to reaction at 37° C. so as to microscopicallymeasure an observance at 650 nm. An activity of said myeloperoxidase wascalculated with a resulting reactant H₂O₂ 1 μmol/ml=1 unit.

(3) Measurement of Inflammatory Indicators

Inflammatory reaction indicator materials such as p-p65, p65, COX-2 andβ-actin were measured by using a western blotting method. Particularly,50 μg of supernatant, which had been obtained by the same method asshown in an experiment for measuring the activity of saidmyeloperoxidase (MPO), was taken and subjected to immunoblotting. Also,an expression level of cytokines (IL-17 and TNF-α) was measured by usingELISA kit.

(4) Experimental Results

The experimental results performed as above are the same as shown in afollowing table 6.

TABLE 6 Weight Colon MPO NF-kB Experimental change length activity TNF-αIL-17 activity COX-2 group g cm μU/mg pg/mg pg/mg p-p65/p65 activityNormal 0.9 6.5 0.21 35 17 0.12 0.23 group Induced −1.9 4.4 1.86 265 890.32 0.52 group LP NK3 −0.9 5.2 1.12 89 45 0.23 0.35 BL NK49 −0.7 5.40.87 95 38 0.22 0.36 Mixture −0.7 5.5 0.82 88 35 0.19 0.29 Positive −1.05.1 1.26 105 47 0.25 0.42 control group

Particularly, it was identified that there is no great change in weightof the group dosed with Lactobacillus plantarum NK3, Bifidobacteriumlongum NK49 or a mixture thereof, thereby showing no toxicity. Also,when inducing colitis, a length of colon was decreased. However, in caseof the group dosed with lactic acid bacteria, it was identified thatthere occurs an effect of recovering a length of colon. Furthermore, incase of the group dosed with lactic acid bacteria, it was identifiedthat an activity of myeloperoxidase, which is increased according toinduced colitis, is decreased, an expression level of TNF -a and IL-17cytokines is inhibited, and activities of NF-kB and COX-2 are inhibited.

From the results, it was identified that the novel lactic acid bacteriahave an effect of preventing and treating colitis, without showing anytoxicity.

Accession Information of Lactic Acid Bacteria

The present inventors deposited Lactobacillus plantarum NK3 for thepurpose of patent to the Korean Culture Center of Microorganisms, acertified depository institution (address: Yulim Building, 45, Hongjenae2ga-gil, Seodaemun-gu, Seoul, South Korea) on August 4, 2017, andreceived an accession number of KCCM12089P.

Also, the present inventors deposited Bifidobacterium longum NK49 forthe purpose of patent to the Korean Culture Center of Microorganisms, acertified depository institution (address: Yulim Building, 45, Hongjenae2ga-gil, Seodaemun-gu, Seoul, South Korea) on August 4, 2017, andreceived an accession number of KCCM12088P.

1.-20. (canceled)
 21. A method of treating an inflammatory diseasecomprising administering to a mammalian subject having a symptom of thedisease an effective amount of Lactobacillus plantarum NK3 having theaccession number KCCM12089P, wherein said inflammatory disease is atleast one selected from the group consist of gastritis, enteritis,nephritis, colitis, urethritis, cystitis and vaginitis.
 22. The methodof claim 21, wherein said inflammatory disease is colitis or vaginitis.23. The method of claim 21, wherein the Lactobacillus plantarum NK3having the accession number KCCM12089P comprises the 16S rDNA sequenceof SEQ ID NO:
 1. 24. The method of claim 21, wherein the Lactobacillusplantarum NK3 having the accession number KCCM12089P is a live bacterialcell thereof or a dead bacterial cell thereof.
 25. The method of claim21, wherein said administering is oral or intravaginal administering.26. The method of claim 21, wherein said inflammatory disease is colitisand said administering is oral administering.
 27. The method of claim21, wherein the said inflammatory disease is vaginitis and saidadministering is oral or intravaginal administering.
 28. The method ofclaim 21, wherein the effective amount is 1×10² to 1×10¹¹ CFU/kg a day.